First Trimester Screening for Preeclampsia and Intrauterine Growth RestrIction Using Three Dimensional Doppler Angiography
SPIRIT
1 other identifier
interventional
2,159
1 country
1
Brief Summary
Introduction: Preeclampsia (PE) and intrauterine growth restriction (IUGR) are two major pregnancy complications, related to a chronic utero-placental hypoperfusion. Nowadays, there isn't a screening or diagnostic test in clinic for utero-placental vascularization deficiency. Since 2004, 3D Power Doppler angiography has been used for the evaluation of utero-placental vascularisation and three vascular indices have been calculated: the vascularisation index (VI), flow index (FI) and vascularisation-FI (VFI). A high intra and inter-observer reproducibility and its potential interest for placental function study were reported. The investigator's main hypothesis is that these 3DPD indices could provide predictive values for PE and/or IUGR occurrence much higher than those observed with the currents other markers. Objectives: The main objective of this study is to determine differences in 3DPD indices at first trimester between pregnancies defined at their outcome as uncomplicated pregnancy, PE (mild and severe) and IUGR in nulliparous women. Methods and analysis: This is a prospective study. The investigators expect to include 2200 women in 4 French centers: Centre Hospitalier Universitaire de Nancy, Paris-Port-Royal (Assistance Publique - Hôpitaux de Paris), Strasbourg and Belfort (Hôpital Nord Franche-Comté). The nulliparous pregnant women will be recruited during their 1st trimester consultation for routine Down syndrome screening (11-13+6 gestation weeks). Especially for the study, the 3DPD and Uterine Artery Doppler (UAD) acquisition, which last less than 10 min, will be included in the current routine 11-13+6 gestation weeks ultrasound screening. Also, additional blood samples will be taken for biomarker analysis (PAPP-A and P1GF) and biological collection. Utero-placental vascularization indices (VI, FI, VFI) will be quantified using VOCAL® software. For each subgroup (uncomplicated pregnancy, PE and IUGR) mean values in 3DPD indices will be computed and compared using a pairwise t test with a Bonferroni correction p value adjustment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Apr 2018
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 8, 2017
CompletedFirst Posted
Study publicly available on registry
November 14, 2017
CompletedStudy Start
First participant enrolled
April 16, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 14, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
November 14, 2022
CompletedDecember 12, 2022
December 1, 2022
4.6 years
November 8, 2017
December 9, 2022
Conditions
Outcome Measures
Primary Outcomes (3)
Measure of 3D power Doppler indice : the vascularization index (VI)
through study completion, an average of 40 months
Measure of 3D power Doppler indice : the flow index (FI)
through study completion, an average of 40 months
Measure of 3D power Doppler indice : the vascularization-flow index (VFI)
through study completion, an average of 40 months
Study Arms (1)
All patients
EXPERIMENTALAll patients will have the same intervention (3DPD and UAD acquisitions ; blood sample)
Interventions
A blood sampling (20 mL) is collected for biomarker analysis (PAPP-A and PlGF) and biological collection.
Eligibility Criteria
You may qualify if:
- Singleton nulliparous pregnant women between 11 and 13+6 gestation weeks.
- Mandatory enrolment in a social security plan,
- Patient (or a third person, independent from the investigator and the sponsor, in case of inability to read or write) having signed an informed consent.
You may not qualify if:
- Patients under a measure of legal protection.
- Patient under 18,
- Absence of social insurance,
- Patient participating simultaneously to other interventional research trial to test a pharmaceutical treatment and protocols are not compatible,
- Inability to understand and accept the protocol.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Centre Hospitalier Régional Universitaire de Nancy
Vandœuvre-lès-Nancy, 54500, France
Related Publications (1)
Bertholdt C, Hossu G, Banasiak C, Beaumont M, Morel O. First trimester screening for pre-eclampsia and intrauterine growth restriction using three-dimensional Doppler angiography (SPIRIT): protocol for a multicentre prospective study in nulliparous pregnant women. BMJ Open. 2020 Oct 19;10(10):e037751. doi: 10.1136/bmjopen-2020-037751.
PMID: 33077562DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
November 8, 2017
First Posted
November 14, 2017
Study Start
April 16, 2018
Primary Completion
November 14, 2022
Study Completion
November 14, 2022
Last Updated
December 12, 2022
Record last verified: 2022-12
Data Sharing
- IPD Sharing
- Will not share